MedTrace Logo

Ketamine to Treat Patients With Post-comatose Disorders of Consciousness

NCT05343507 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-11-07

No results posted yet for this study

Summary

The investigators will run a Randomized Clinical Trial with 30 patients with disorders of consciousness (DoC), with intravenous subanesthetic doses of ketamine. Patients will simultaneously undergo TMS-EEG. The piloting will be done on 3 patients, with EEG only.

Conditions

  • Disorder of Consciousness

Interventions

DRUG

Ketalar 50 MG/ML Injectable Solution

Intravenous solution (other info already provided)

DRUG

Placebo

Saline Solution

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Liege

    collaborator OTHER

  • William Lennox Neurological Center UCLouvain

    collaborator UNKNOWN

  • University of Liege

    lead OTHER

Principal Investigators

  • Olivia Gosseries, PhD · Coma Science Group (ULiege) & Centre du Cerveau2 (CHU Liege)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2025-05-01
Completion
2026-05-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05343507 on ClinicalTrials.gov